In the Phase II clinical trial of the use of DEX in non-small cell lung cancer (NSCLC), they are testing the clinical benefit of γ-Dex (exosomes derived from IFN-γ-treated DC) as a maintenance immunotherapy in cancer patients at stage IIIB-IV, responding to or stabilized with, cisplatin-based chemotherapy [114]. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.